Pliant Therapeutics Dividends and Buybacks
Dividend criteria checks 0/6
Pliant Therapeutics does not have a record of paying a dividend.
Key information
n/a
Dividend yield
-0.4%
Buyback Yield
| Total Shareholder Yield | -0.4% |
| Future Dividend Yield | 0% |
| Dividend Growth | n/a |
| Next dividend pay date | n/a |
| Ex dividend date | n/a |
| Dividend per share | n/a |
| Payout ratio | n/a |
Recent dividend and buyback updates
No updates
Recent updates
Is Pliant Therapeutics (NASDAQ:PLRX) Using Too Much Debt?
Sep 13
Pliant Therapeutics: Good Data, But Will Need Watching
Sep 11Should Shareholders Reconsider Pliant Therapeutics, Inc.'s (NASDAQ:PLRX) CEO Compensation Package?
Jun 07Is Pliant Therapeutics (NASDAQ:PLRX) Weighed On By Its Debt Load?
Feb 27Is Pliant Therapeutics (NASDAQ:PLRX) Using Debt Sensibly?
Jul 21Health Check: How Prudently Does Pliant Therapeutics (NASDAQ:PLRX) Use Debt?
Mar 13Is Pliant Therapeutics (NASDAQ:PLRX) Weighed On By Its Debt Load?
Sep 10Pliant Therapeutics: Wait For A Better Price To Get In
Aug 20Pliant Therapeutics GAAP EPS of -$0.82 misses by $0.01, revenue of $4.99M
Aug 08Is Pliant Therapeutics (NASDAQ:PLRX) In A Good Position To Deliver On Growth Plans?
Jul 28Pliant's PLN-74809 gets FDA fast track status for liver disease
Jul 21Pliant climbs 48% as mid-stage trial for lung disease therapy meets key goals
Jul 11Pliant: Major Catalyst Expected Beginning Of 2023
Jun 03We're Keeping An Eye On Pliant Therapeutics' (NASDAQ:PLRX) Cash Burn Rate
Apr 22Here's Why We're Not Too Worried About Pliant Therapeutics' (NASDAQ:PLRX) Cash Burn Situation
Dec 29We Think Pliant Therapeutics (NASDAQ:PLRX) Can Afford To Drive Business Growth
Sep 07Analysts Have Just Cut Their Pliant Therapeutics, Inc. (NASDAQ:PLRX) Revenue Estimates By 12%
May 17Pliant Therapeutics, Inc. (NASDAQ:PLRX) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates
May 13Pliant Therapeutics (NASDAQ:PLRX) Is In A Good Position To Deliver On Growth Plans
Mar 22Stability and Growth of Payments
Fetching dividends data
Stable Dividend: Insufficient data to determine if PLRX's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if PLRX's dividend payments have been increasing.
Dividend Yield vs Market
| Pliant Therapeutics Dividend Yield vs Market |
|---|
| Segment | Dividend Yield |
|---|---|
| Company (PLRX) | n/a |
| Market Bottom 25% (US) | 1.4% |
| Market Top 25% (US) | 4.3% |
| Industry Average (Pharmaceuticals) | 2.4% |
| Analyst forecast (PLRX) (up to 3 years) | 0% |
Notable Dividend: Unable to evaluate PLRX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate PLRX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate PLRX's payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as PLRX has not reported any payouts.